ziprasidone has been researched along with Metabolic Syndrome in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Coid, J; Deng, W; Guo, W; Hu, X; Li, K; Li, L; Li, T; Li, X; Li, Y; Lu, T; Lv, L; Ma, X; Ren, H; Reynolds, GP; Tan, L; Tan, Q; Tian, Y; Wang, C; Wang, H; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Chen, AP; Juang, YY; Lee, CP | 1 |
| Li, CH; Rao, SZ; Shi, L; Zhan, GL; Zhang, H | 1 |
| Chue, P; Mandel, FS; Therrien, F | 1 |
| Bai, YH; Cai, M; Chen, YC; Guo, L; McAlonan, GM; Tan, QR; Wang, HH; Wang, HN; Wang, Y; Wu, WJ; Zhang, RG; Zhang, YH; Zhang, ZJ | 1 |
| Dadić-Hero, E; Grahovac, T; Palijan, TZ; Petranović, D; Ružić, K; Sepić-Grahovac, D | 1 |
| Dadić-Hero, E; Grahovac, T; Ružić, K; Sabljić, V; Sepić-Grahovac, D | 1 |
| Kaushik, S; Khan, A; Lindenmayer, JP; Parakadavil, M; Smith, RC; Tedeschi, F; Yusim, A | 1 |
| Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
5 trial(s) available for ziprasidone and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides | 2020 |
A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Triglycerides | 2013 |
The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Risk Factors; Schizophrenia; Thiazoles; Young Adult | 2014 |
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome; Weight Gain | 2017 |
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
5 other study(ies) available for ziprasidone and Metabolic Syndrome
| Article | Year |
|---|---|
Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.
Topics: Adult; Antipsychotic Agents; Female; Humans; Metabolic Syndrome; Piperazines; Polypharmacy; Schizophrenia, Paranoid; Thiazoles; Weight Gain | 2015 |
Antipsychotic treatment--side-effect and/or metabolic syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Drug Substitution; Female; Humans; Metabolic Syndrome; Olanzapine; Piperazines; Psychotherapy; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Weight Gain | 2011 |
Weight gain--as possible predictor of metabolic syndrome.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dibenzothiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Metabolic Syndrome; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Thiazoles; Weight Gain | 2011 |
Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Insulin; Lipids; Male; Metabolic Syndrome; Middle Aged; Piperazines; Polypharmacy; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |